http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102256991-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 |
| filingDate | 2009-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102256991-B |
| titleOfInvention | Uracyl cyclopropyl nucleotides |
| abstract | Formula I, comprises its any possible steric isomer, wherein: Rn 1 hydrogen or halo; Rn 4 monophosphate ester group, bisphosphate ester group or triphosphoric acid ester group; Or Rn 4 it is the group of formula (II); Rn 7 the optional phenyl, naphthyl, indyl or the N-C that replacen 1 -Cn 6 carbalkoxy indyl; Rn 8 hydrogen, Cn 1 -Cn 6 alkyl, benzyl; Rn 8 ' hydrogen, Cn 1 -Cn 6 alkyl, benzyl; Or Rn 8 and Rn 8 ' c is formed together with the carbon atom that they connectn 3 -Cn 7 cycloalkyl; Rn 9 cn 1 -Cn 10 alkyl, benzyl or the optional phenyl replaced; Or its pharmacy acceptable salt or solvate, pharmaceutical preparation and Compound I are as the purposes of HCV inhibitor. |
| priorityDate | 2008-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 277.